Fortrea closes purchase of Early Phase Services unit from Worldwide Clinical Trials
Fortrea has closed a roughly $45 million deal for the Early Phase Services unit, adding capacity for early-stage clinical trials across its network.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Contract research organization Fortrea says it has closed its purchase of the Early Phase Services unit from Worldwide Clinical Trials. According to a press release published on GlobeNewswire, the all-cash transaction was valued at about $45 million.
The unit brings a 200-bed clinical research facility in San Antonio, Texas, a 60,000-square-foot bioanalytical laboratory in Austin and a biospecimen storage site in Pflugerville. Fortrea states that its early-phase capacity now exceeds 570 beds worldwide.
Management argues that combining clinical and bioanalytical operations will cut handoffs between teams and speed up turnaround times. Agreements with Worldwide Clinical Trials are meant to keep client projects and staff on track during the transition.
why it matters
The sum is modest for a company of this size, so the deal is a limited market event. Investors may still track it as an example of how CROs are expanding capacity for early-stage drug development.
tags
instruments
sources
- Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials — globenewswire.com, 19 October 2026 at 20:05 UTC
- Fortrea Completes Acquisition Of The Early Phase Services Division From Worldwide Clinical Trials — Reuters, 19 October 2026 at 21:57 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗